Event-free survival (EFS) at 5 years in pediatric acute lymphoblastic leukemia (ALL) is 480%. Outcome in adult ALL is still unsatisfactory, which is due to less cumulative dosing of chemotherapy and less strict adherence to timing of successive cycles. In the present phase II trial, we evaluated a pediatric regimen in adult patients with ALL under the age of 40. Treatment was according to the pediatric FRALLE approach for high-risk ALL patients and characterized by increased dosages of asparaginase, steroids, methotrexate and vincristin. However, allogeneic stem cell transplantation was offered to standard risk patients with a sibling donor and to all high-risk patients in contrast to the pediatric protocol. Feasibility was defined by achieving complete remission (CR) and completion of treatment within a strict timeframe in at least 60% of patients. In all, 54 patients were included with a median age of 26. CR was achieved in 49 patients (91%), of whom 33 completed treatment as scheduled (61%). Side effects primarily consisted of infections and occurred in 40% of patients. With a median follow-up of 32 months, EFS estimated 66% at 24 months and overall survival 72%. These data show that a dose-intensive pediatric regimen is feasible in adult ALL patients up to the age of 40.
Introduction
Intensified and multi-agent chemotherapy is associated with excellent results in children with acute lymphoblastic leukemia (ALL). By alternating and intensifying conventional chemotherapeutic drugs, the event-free survival (EFS) in children has dramatically improved from 71 to 83% in the 1990s to more than 90% nowadays. [1] [2] [3] [4] In contrast, treatment results in adult patients with ALL have only marginally improved during the last decades. Large multicenter studies in adult patients reported 5-year EFS of only 30-50%, despite complete remission (CR) rates between 70-90%. [5] [6] [7] [8] Poor survival in adult patients is remarkable and might be explained by several causes. First, biological characteristics of the disease might differ while secondly, the intensity of the treatment varies markedly between treatment protocols in children and adults, as was underlined by several major ALL trial groups. [9] [10] [11] [12] [13] [14] Major differences between pediatric and adult treatment approaches include the actually given dosages of non-myelotoxic therapy (asparaginase, corticosteroids, methotrexate and vinca-alkoids) and the strict timing of subsequent courses of chemotherapy in children.
Therefore, in order to improve outcome in adult patients, several groups have adjusted treatment by incorporating intensified courses guided by current pediatric protocols. A recent Group for Research on Adult Acute Lymphoblastic Leukemia study suggested that such pediatric inspired approach may markedly improve outcome in adult ALL. 15 However, the question whether a pediatric protocol might be feasible in adults remains to be answered as well as the question of the upper age limit. Therefore, the Dutch-Belgian HOVON study group investigated whether an intensive pediatric regimen based on the FRALLE 93 16 high-risk scheme would be feasible in adults with newly diagnosed ALL up to the age of 40, including BCR-ABL-positive ALL.
Patients and methods

Patients
The HOVON 70 study was conducted in 15 
Diagnosis of ALL
Baseline evaluation included morphology of the bone marrow (ALL was diagnosed if more than 20% lymphoblasts were detected) and immunophenotyping, which were centrally reviewed. Cytogenetic evaluation and molecular analysis for BCR-ABL and MLL-AF4 were conducted in the particular institutions. Central nervous system involvement was diagnosed if there were clinical neurological signs and/or greater than 5 Â 10 3 blast cells/l cerebrospinal fluid.
Response criteria
CR was defined as less than 5% leukemic cells by morphology in normocellular bone marrow, no peripheral blood leukemic cells and no evidence of extramedullary disease.
Risk groups
Patients were classified as having high-risk disease if they met one of the following criteria at baseline: white blood cell count greater than 30 Â 10 9 /l for B-ALL or greater than 100 Â 10 9 /l for T-ALL and presence of t(9;22) or t(4;11) or one of their fusion gene products (BCR-ABL, MLL-AF4). In addition, patients not reaching CR after remission induction were also considered high risk.
Treatment regimen
The drugs and dosages of chemotherapy based on the children FRALLE 93 study protocol for high-risk disease are listed in Table 1, including cumulative doses. 9,17 After a 7-day prednisone pre-phase, patients proceeded with a multidrug remission induction course (Table 1) . Patients in CR or partial remission, hematological recovery and without severe organ dysfunction went on with the consolidation regimen containing 5000 mg/m 2 methotrexate twice. Each treatment phase after remission induction consisted of an A and a B part (Table 1 ). This was followed by two intensifications (IA&B and IIA&B) with intensified Escherichia coli L-asparaginase (6000 IU/m 2 ), interspersed by an interphase (A&B) with again two-times high-dose methotrexate. Maintenance chemotherapy was given for up to 2 years after the start of pre-phase. Central nervous system prophylaxis was delivered intrathecally 18 times throughout the protocol. Cranial irradiation was only given in patients with meningeal involvement after intensification course IA&B, provided the patient did not proceed to alloSCT. All patients were given daily low-dose trimethoprim/sulfamethoxazole for pneumocystis prophylaxis and valaciclovir for herpes prophylaxis throughout the protocol. During remission induction, ciprofloxacin and fluconazole were strongly recommended. Granulocyte colony-stimulating factor was not mandatory during treatment. Patients with t(9;22) positivity received imatinib 600 mg daily in conjunction with chemotherapy. Allogeneic stem cell transplantation (alloSCT) was scheduled after intensification course IA&B, with alloSCT from a sibling donor in case of standard-risk ALL and high-risk patients also qualifying for unrelated donor alloSCT. Application of alloSCT in our study differs from the original FRALLE protocol where only patients in CR with high-risk disease and an HLA-identical sibling were allografted. Conditioning regimen before alloSCT consisted of high-dose cyclophosphamide combined with total body irradiation 2 Â 6 Gy.
Endpoints and statistical methods
This study was designed as a non-randomised, prospective and multicenter phase II clinical trial. The primary endpoint was feasibility as defined by the percentage of patients that reached CR, completed all phases of the protocol, started with maintenance therapy within 49 weeks after the start of pre-phase and/or received an alloSCT within 34 weeks after the start of pre-phase. Chemotherapy only takes a miminum of 41 weeks if no complications occur (see Table 1 ), but should not exceed 49 weeks, which appeared a reasonable goal. Chemotherapy before alloSCT takes a minimum of 24 weeks (see Table 1 ), which may therefore be completed in most patients within 30 weeks, to which 4 weeks were added to prepare for the allograft. The approach would be considered feasible if that percentage would exceed 60% of all patients entered. In addition, if the upper limit of the 90% confidence interval of this percentage would be less than 70%, the schedule would be considered not feasible in adult ALL. The secondary end-points were CR rate, toxicity profile related to each treatment cycle, EFS and overall survival (OS). EFS was defined as time from registration until no CR on protocol, relapse or death, whichever came first. OS was measured from registration of remission until death from any cause. Adverse events and infections were scored according to the NCI Common Terminology Criteria for Adverse Events (CTC, version 3.0, published December 2003). EFS and OS were estimated by the Kaplan-Meier method, and 95% confidence intervals were constructed. Survival endpoints were illustrated by the Kaplan-Meier survival curves.
Results
Patient characteristics
Patient's main characteristics are presented in Table 2 . A total of 54 patients entered the study. The median age was 26 years (range 17-39 years). In all, 36 patients (67%) presented with precursor B-cell immunophenotype, 16 patients (30%) with precursor T-cell immunophenotype and 2 (3%) with biphenotypic leukemia. Extramedullary involvement was present in 29/54 patients (54%). Cytogenetic evaluation was successful in 49 patients; t(9;22) was noted in 9/49 (18%) of the patients and t(4;11) in 2 patients (4%). In total, 23 out of 54 patients (43%) were classified as having high-risk disease.
Response to remission induction CR was achieved in 49/54 (91%) patients. Failures to reach CR included death in two patients (respectively due to fatal pulmonary embolism and septic shock caused by Pseudomonas aeruginosa) and refractory disease in two patients. One patient went off protocol before response evaluation after a subdural hematoma. The CR rate of patients with t(9;22) was 9/9 patients (including seven after remission-induction) (100%) and 2/2 patients with t(4;11). CR was achieved in 36/40 (90%) in BCR-ABL-negative patients.
Post-induction treatment
Eight patients (15%) received no consolidation treatment because of failure to achieve CR in three patients, toxicity after induction therapy in two patients, non-relapse mortality in two patients and refusal to proceed in one patient (Figure 1 ). Treatment according to protocol was completed by 38 patients, including 19 recipients of an alloSCT. A total of 10 (53%) of these transplanted patients had high-risk ALL. In all, 13 transplanted patients remained in continuous remission. Five patients died after transplantation, including two relapsed ALL and three as a result of complications (non-relapse mortality).
Feasibility
Feasibility was defined by both achieving CR and completion of chemotherapy within a strict timeframe. A total of 33 out of 54 patients (61% (95% confidence interval: 49-72%)) entered CR and also completed chemotherapy within the predefined timeframe, which was 49 weeks for maintenance chemotherapy and 34 weeks for alloSCT. Four patients started maintenance beyond the predefined time of 49 weeks by a median delay of 20 days (range 14-26), and one patient received his planned alloSCT 29 Pediatric approach in adult ALL AW Rijneveld et al days after 34 weeks, which was the time limit set for alloSCT. Chemotherapy could not be given as originally scheduled in 21 patients due to delay and/or toxicity (n ¼ 18) or due to refractory disease (n ¼ 3) (Figure 1 ). Treatment according to protocol was completed by 18 out of 19 CR patients scheduled for alloSCT and by 16 out of 20 patients in continued CR and lacking excessive toxicity, who were scheduled for maintenance.
EFS and OS
The estimated 2-year EFS en OS were 66% (95% confidence interval: 52-77) and 72% (95% confidence interval: 58-82), respectively, for the entire group of patients (Figure 2a) . For standard risk patients, EFS and OS were 87%, while EFS and OS at 2 years estimated 43% and 57%, respectively, in high-risk patients (Figure 2b ). Median age was the same in both prognostic groups. Since 19 patients received an alloSCT, we also estimated outcome for chemotherapy-treated patients only, by censoring patients at the time of alloSCT. EFS and OS were 73% and 80% respectively (data not shown). The median follow-up of 38 surviving patients was 32 (range 22-45) months.
Toxicity
Feasibility of increased dosages of especially asparaginase, steroids, methotrexate and vincristin was evaluated in terms of grade 3-4 CTC toxicity (Table 3) as well as in terms of scheduling. Throughout the protocol, three toxic deaths were reported: one due to pulmonary embolism and two due to septic shock. Asparaginase showed acceptable toxicity, with one CTC grade 4 thromboembolic event and three patients showing severe liver disturbances (CTC grade 4). No pancreatitis and one allergic reaction to asparaginase was observed. Most thromboembolic events were noticed during the induction phase (7/54, 13%), while subsequent asparaginase administrations, during intensification phase I and II, were largely uneventful.
Intensified steroid dosing may increase susceptibility to infections and these were reported in approximately 40% of patients during induction as well as consolidation (CTC grade 3-4) ( Table 3) . Six possible fungal infections were noticed. Most episodes of infections were classified as neutropenic fever without positive cultures of blood or other specimen. Avascular bone necrosis was confirmed in one patient only, and one patient presented with hip pain without x-ray abnormalities, but magnetic resonance imaging was not performed. High-dose methotrexate caused renal failure in three patients, which resolved completely in all of them. Severe mucositis was reported in three patients after high-dose methotrexate administration, necessitating total parenteral nutrition for a short period of time. Neurological side effects were reported in 20% of the patients during induction and 17% during consolidation, and mainly consisted of polyneuropathy due to vincristin. Maintenance treatment was in general feasible. Remarkably, during maintenance treatment 55% of the patients encountered liver enzyme disorders. Most likely, these were caused by transient hepatotoxicty due to methotrexate, as only one of the patients stopped methotrexate administration completely. Four patients stopped and did not receive vincristin during reinduction courses and maintenance at all. In one of these patients vincristin was replaced by vindesine, as vindesine is known to be associated with less neurological toxicity. In four other patients the dose was reduced because of polyneuropathy. Collectively, it was concluded that the major toxicity encountered during the protocol-treatment was infectious toxicity, and toxicity was not confined to a particular treatment course.
Discussion
Recent studies suggested that treatment results in adult ALL might improve by incorporating elements guided by pediatric protocols. 15, 17 However, the question whether a pediatric scheme designed for high-risk patients might be feasible and efficacious in adult patients up to the age of 40, has remained open. The present prospective, non-randomized study shows that a pediatric approach is feasible in adult ALL patients up to the age of 40 years. It is demonstrated that a high CR rate and favorable EFS and OS can be obtained without excessive toxicity.
Although a CR rate of approximately 90% was obtained earlier in adult ALL, improvement of EFS has lacked behind. [2] [3] [4] [5] [6] [7] [8] 18 Especially, intensification of consolidation and post-consolidation courses is considered to exert the greatest impact on remission duration and EFS. An EFS of 69% at 2 years in the present study suggests an improvement compared with previous results by the HOVON cooperative group. 5 In that study, a subgroup analysis for patients up to the age of 40 (n ¼ 262) showed an EFS at 2 years of 54 and 42% for patients with a donor versus those without a donor. The favorable outcome was especially observed in patients with a standard risk profile, who showed an OS of 87% which compares favorably with an OS of 59% as was observed before in standard-risk patients. 5 However, also high-risk patients seem to benefit, as suggested by an OS of 57% at 2 years compared with 40% in the recent HOVON studies. 5 However, longer follow-up is needed for a more mature comparison.
Several retrospective reports have shown that adolescents treated with pediatric protocols have a superior outcome compared with similarly aged patients treated with adult protocols. However, these studies focused on patients aged 15-21 years, leaving the question open whether such intensification would be feasible in patients beyond 20 years of age. Pediatric protocols have been applied to a limited degree by several other groups with most patients being below 25 years of age. [19] [20] [21] In this study, we evaluated the tolerability of an intensified chemotherapeutic drug regimen, but also evaluated the application of a strict time-schedule with a dose-dense approach according to the pediatric approach. Three patients died because of toxicity, while approximately 40% experienced CTC grade 3-4 infectious complications during induction as well as consolidation, suggesting that toxicity may limit further intensification of treatment in adult ALL. Toxicity appeared mainly related to infections. Therefore, addition of specific antimicrobial prophylaxis and growth factor support seems warranted. Interestingly, asparaginase and high-dose methotrexate, major components of the post-induction phases, showed acceptable toxicity, with one death due to a thrombo-embolic event after asparaginase administration. Thrombo-embolic events were encountered primarily during induction, while all other asparaginase administrations were not complicated by thrombotic events. That difference might be explained by the contributory role of active leukemia, steroids and asparaginase to a pro-thrombotic state and a higher risk for thrombo-embolic events. 22, 23 Our definition of feasibility included the completion of chemotherapy within a predefined strict time schedule. Excessive delay in treatment was observed in only five patients, indicating that a disciplinary, dose-dense approach is feasible in adult patients with ALL. An upper age limit of 40 years was adhered to in this study. That limit may be very reasonable in view also of the recent Group for Research on Adult Acute Lymphoblastic Leukemia results and the study of Haiat et al. 15, 17 Importantly, both studies showed that age remains an important adverse risk factor. Collectively, their results and our results strongly suggest that adult patients up to the age of 40 do tolerate high-dose chemotherapy, as is standard in childhood ALL.
In our study, CR was defined as less than 5% leukemic cells by morphology in normocellular bone marrow, no peripheral blood leukemic cells and no evidence of extramedullary disease. MRD diagnostics has recently been proven to have prognostic value not only for pediatric but also for adult ALL [24] [25] and is already used in current pediatric trials to stratify patients. 26 However, minimal residual disease was not detected in our feasibility study. In the current study, we include the standardized estimation of MRD at specific timepoints in order to identify specific risk groups.
As alloSCT was part of the protocol, we also calculated survival for chemotherapy-treated patients only; EFS and OS were 73% and 80%, respectively. Although, the number of patients was small, these favorable results show that improved outcome cannot selectively be ascribed to allogeneic immunotherapy. Moreover, these results evoke the question whether standard-risk patients in CR1 should still qualify for alloSCT from a sibling donor, as is our current policy. However, mature results from larger studies will be needed to define the place of alloSCT in standard-risk patients, as is currently done in AML patients. 27 The question which patients benefit most from alloSCT and in which patients alloSCT should be withheld has gained new significance with our results. Therefore, future studies should incorporate both treatment-related mortality and morbidity as important secondary endpoints when comparing recipients of alloSCT versus recipients of prolonged maintenance chemotherapy.
In conclusion, a pediatric treatment schedule designed for high-risk patients is safe and feasible and appeared associated with encouraging results in adult ALL patients up to the age of 40. Based on that experience, a phase III trial has recently been initiated by HOVON/EORTC.
